- SC Terapia SA — rub by
Sun Pharma —acquired the Uractiv portfolio fromFiterman Pharma . - The portfolio includes dietary supplements including minerals, vitamins and adjuvants.
- The company plans to leverage its marketing and distribution strengths to further develop these brands.
Romanian company SC Terapia SA – a subsidiary of Sun Pharmaceuticals – announced on Friday the acquisition of Fiterman Pharma’s Uractiv portfolio in the European country. Financial terms of the transaction are confidential, the company said.
The portfolio includes dietary supplements including minerals, vitamins and adjuvants as well as cosmetics and medical devices used to maintain urinary tract health. The product line – which was founded ten years ago – has 12 stock-keeping units (SKUs) with annualized sales of $8.7 million as of February 2022.
“We are delighted to add Uractiv to our consumer healthcare portfolio in Romania. This acquisition is in line with our strategy to further expand our basket of non-prescription products in Romania and neighboring markets,” said Aalok Shanghvi, Executive Vice President and Head of Generic R&D, Generic. Global BD and Emerging Markets, Sun Pharma.
Shanghvi also noted that Sun Pharma has a strong presence in Romania thanks to Terapia, the market leader in generic and over-the-counter (OTC) drugs. The company plans to leverage its marketing and distribution strengths to further develop these brands.
The acquisition is subject to customary closing conditions and necessary regulatory approvals.
Sun Pharmaceuticals is one of the leading pharmaceutical companies in India and has a presence in 100 countries across the world. The company has established manufacturing facilities on six continents.
The company’s share price is up nearly 28.6% from a year ago. The shares also rose slightly on Friday and were trading at ₹900.40 as of 11:15 a.m.
SEE ALSO
Paradeep Phosphates posts 9% premium as Sensex and Nifty trade in green
Edtech bubble bursts as schools, colleges reopen and funds dry up
IT jobs are safer than start-up jobs, but a wage bubble awaits them
